The agency issued the warning against three brands of unapproved eyedrops designed to look like an approved brand.
Be careful what you put in your eye.
FDA has issued a warning for consumers to be on the lookout for copycat eyedrops.1 Specifically, consumers should be wary of purchasing eye drops that are designed to look like Bausch + Lomb’s Lumify brand. While Lumify is approved for redness relief, the noted brands are not approved by FDA.
The brands are as follows: South Moon, Rebright, and FivFivGo.
The agency’s warning was posted with an image showing how the three brands packaging and branding is designed to look exactly like Lumify. While each brand is clearly marked with its own name, the box’s all use the same color scheme and each feature the same drawing of a women’s eye with a purple tint to it. The drug information is also laid out in the same exact pattern on each box.
The medication itself is also packaged in a similar container to Lumify, with a short white plastic bottle and a purple top. FDA points out, however, that these images are how the medications are marketed on websites and that the actual packaging and containers may appear different in person.
According to FDA, the risk of using these copycat products goes beyond just being duped as a consumer. Two brands, South Moon and Rebright, were tested by the agency. The South Moon sample was found to be contaminated with Burkholderia cepacia, which is a bacteria that can cause an anti-biotic resistant infection.
The Rebright sample did not show any signs of contamination. FDA was unable to obtain a sample of FivFivGo. Regardless, the agency is still warning against the use of each brand. This is partially due to reports that agency has received claiming that fake Lumify medications have caused eye irritation, pain, and infection.
Neither Rebright or South Moon were found to contain the active ingredient of Lumify, brimonidine tartrate.
In a statement obtained by CNN, a spokesperson for Bausch + Lamb said, “Consumers can be confident that authentic Lumify redness reliever eye drops are made with the highest standards of safety and efficacy. We’re working closely with the FDA and our authorized retail partners to help protect individuals from copycat products.”2
This is just the latest example of fake medication that can potentially cause harm appearing on the market.
In late January, Pharmaceutical Executive reported that three US residents potentially ingested a counterfeit version of Ozempic, a popular weight-loss drug.3 The three victims experienced hypoglycemia, which is believed to be a result of the counterfeit medication. Ozempic is a highly popular medication and many consumers have had trouble getting their hands on it. This created a highly advantageous situation for counterfeit drug makers.
FDA urges consumers to avoid counterfeit medications and to only purchase medications from reputable sources, such as state-licensed pharmacies.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Recent Developments in Pharmaceutical Validation
November 1st 2024Explore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape.